Truqap 200 mg

Truqap 200 mg is a medication containing capivasertib, used to treat certain types of cancer. This oral tablet is manufactured by AstraZeneca Canada Inc. and is designed for targeted therapy.

Truqap 200 mg is primarily used in the treatment of specific cancers. Capivasertib, the active ingredient, is often prescribed in combination with other therapies to target cancer cells. Patients may wonder, 'What is Truqap used for?' It is typically used for conditions where targeted therapy is beneficial.

Common effects of Truqap 200 mg may include gastrointestinal issues such as diarrhea or nausea. Some patients may experience fatigue or changes in blood cell counts. These effects can vary and are not exhaustive; individual experiences may differ.

Truqap 200 mg should be handled with care, following the advice of a healthcare professional. It is important to store the medication properly and to be aware of any potential allergies or sensitivities. Regular monitoring may be required during treatment.

Truqap 200 mg may interact with certain medications, including those that affect the liver's ability to metabolize drugs. Alcohol and other substances that impact liver function should be discussed with a healthcare provider to avoid potential interactions.